NCT07511504 2026-04-06Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular CarcinomaOHSU Knight Cancer InstitutePhase 2 Not yet recruiting40 enrolled